80 related articles for article (PubMed ID: 2822901)
1. Extinction of mineralocorticoid effects in 19-norprogesterone derivatives: structure-activity relationships.
Paris J; Botella J; Fournau P; Bonnet P; Thevenot R
J Pharmacol Exp Ther; 1987 Oct; 243(1):288-91. PubMed ID: 2822901
[TBL] [Abstract][Full Text] [Related]
2. Progestogens with antimineralocorticoid activity.
Losert W; Casals-Stenzel J; Buse M
Arzneimittelforschung; 1985; 35(2):459-71. PubMed ID: 4039568
[TBL] [Abstract][Full Text] [Related]
3. 19-Nor progesterone is a mineralocorticoid agonist.
Funder JW; Adam WR
Endocrinology; 1981 Jul; 109(1):313-5. PubMed ID: 6263590
[TBL] [Abstract][Full Text] [Related]
4. Interaction of new 19 nor progesterone derivatives with progestagen, mineralocorticoid and glucocorticoid cytosolic receptors.
Botella J; Porthe-Nibelle J; Paris J; Lahlou B
J Pharmacol; 1986; 17(4):699-706. PubMed ID: 3560978
[TBL] [Abstract][Full Text] [Related]
5. Mineralocorticoid and hypertensive effects of 19-nor-progesterone.
Hall CE; Gomez-Sanchez CE; Hungerford S; Gomez-Sanchez EP
Endocrinology; 1981 Oct; 109(4):1168-75. PubMed ID: 7285865
[TBL] [Abstract][Full Text] [Related]
6. Affinity of 18,19-dihydroxydeoxycorticosterone and 18-hydroxy-19-nor-deoxycorticosterone to aldosterone receptor and their mineralocorticoid activity.
Okamoto M; Momoi K; Yamano T; Nakamura M; Odaguchi K; Shimizu T; Okada T; Terasawa T
Biochem Int; 1983 Dec; 7(6):687-94. PubMed ID: 6237653
[TBL] [Abstract][Full Text] [Related]
7. Relationships of the molecular structure of aldosterone derivatives with their binding affinity for mineralocorticoid receptor.
Yamakawa M; Ezumi K; Shiro M; Nakai H; Kamata S; Matsui T; Haga N
Mol Pharmacol; 1986 Dec; 30(6):585-9. PubMed ID: 3023811
[TBL] [Abstract][Full Text] [Related]
8. Excretion of electrolytes in Brown Norway and Fischer 344 rats: effects of adrenalectomy and of mineralocorticoid and glucocorticoid receptor ligands.
Marissal-Arvy N; Mormède P
Exp Physiol; 2004 Nov; 89(6):753-65. PubMed ID: 15364879
[TBL] [Abstract][Full Text] [Related]
9. Renal receptor-binding activity of reduced metabolites of aldosterone: evidence for a mineralocorticoid effect outside of the classic aldosterone receptor system.
Gomez-Sanchez CE; Smith JS; Ferris MW; Gomez-Sanchez EP
Endocrinology; 1984 Aug; 115(2):712-5. PubMed ID: 6086276
[TBL] [Abstract][Full Text] [Related]
10. Mineralocorticoid like effect of new 18-hydroxy-steroid isolated from urine of hypertensive patients.
Palem-Vliers M; Fontaine F; Genard P
Endocrinol Exp; 1976 Mar; 10(1):59-63. PubMed ID: 1083802
[TBL] [Abstract][Full Text] [Related]
11. The renal action of spirorenone and other 6 beta,7 beta; 15 beta,16 beta-dimethylene-17-spirolactones, a new type of steroidal aldosterone antagonists.
Casals-Stenzel J; Buse M; Wambach G; Losert W
Arzneimittelforschung; 1984; 34(3):241-6. PubMed ID: 6329237
[TBL] [Abstract][Full Text] [Related]
12. Sodium-retaining activity of some natural and synthetic 21-deoxysteroids.
Burton G; Galigniana M; De Lavallaz S; Brachet-Cota AL; Sproviero EM; Ghini AA; Lantos CP; Damasco MC
Mol Pharmacol; 1995 Mar; 47(3):535-43. PubMed ID: 7700251
[TBL] [Abstract][Full Text] [Related]
13. 19-nor analogs of adrenal steroids: mineralocorticoid and glucocorticoid receptor activity.
Wynne KN; Mercer J; Stockigt JR; Funder JW
Endocrinology; 1980 Nov; 107(5):1278-80. PubMed ID: 6253261
[TBL] [Abstract][Full Text] [Related]
14. The mechanism of mineralocorticoid action of carbenoxolone.
Armanini D; Karbowiak I; Krozowski Z; Funder JW; Adam WR
Endocrinology; 1982 Nov; 111(5):1683-6. PubMed ID: 6290195
[TBL] [Abstract][Full Text] [Related]
15. Potassium prorenoate: a new steroidal aldosterone antagonist.
Hofmann LM; Chinn LJ; Pedrera HA; Krupnick MI; Suleymanov OD
J Pharmacol Exp Ther; 1975 Aug; 194(2):450-6. PubMed ID: 1151770
[TBL] [Abstract][Full Text] [Related]
16. Mespirenone and other 15,16-methylene-17-spirolactones, a new type of steroidal aldosterone antagonists.
Losert W; Bittler D; Buse M; Casals-Stenzel J; Haberey M; Laurent H; Nickisch K; Schillinger E; Wiechert R
Arzneimittelforschung; 1986 Nov; 36(11):1583-600. PubMed ID: 3028435
[TBL] [Abstract][Full Text] [Related]
17. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Jan; 424():1-304. PubMed ID: 12616287
[TBL] [Abstract][Full Text] [Related]
18. Antinatriuretic and kaliuretic activities of the reduced derivatives of aldosterone.
Kenyon CJ; Brem AS; McDermott MJ; Deconti GA; Latif SA; Morris DJ
Endocrinology; 1983 May; 112(5):1852-6. PubMed ID: 6403339
[TBL] [Abstract][Full Text] [Related]
19. Aldosterone receptor measurements during changes in dietary sodium.
Grekin RJ; Sider RS
Endocrinology; 1981 Jan; 108(1):109-12. PubMed ID: 6450676
[TBL] [Abstract][Full Text] [Related]
20. Comparative inhibition by hard and soft metal ions of steroid-binding capacity of renal mineralocorticoid receptor cross-linked to the 90-kDa heat-shock protein heterocomplex.
Galigniana MD; Piwien-Pilipuk G
Biochem J; 1999 Aug; 341 ( Pt 3)(Pt 3):585-92. PubMed ID: 10417321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
